Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vanucizumab in adults with advanced solid tumors refractory to standard therapies

Trial Profile

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vanucizumab in adults with advanced solid tumors refractory to standard therapies

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs Vanucizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 19 Dec 2017 New trial record
    • 07 Dec 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top